Creative Medical Technology Holdings (CELZ) Cash from Operations (2011 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Cash from Operations of 1323310.0 for Q1 2026, up 16.85% year-over-year from 1132454.82 in Q1 2025, and up 31.7% quarter-over-quarter from 1937554.0 in Q4 2025.
Creative Medical Technology Holdings (CELZ) Cash from Operations (2011 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Cash from Operations for 16 consecutive years, with 1323310.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 16.85% year-over-year to 1323310.0; the TTM figure through Mar 2026 stood at 5588220.0 (up 6.8% YoY), while the FY2025 annual figure was 5856445.0, down 10.47% from the prior year.
- Cash from Operations advanced to 1323310.0 in Q1 2026 per CELZ's latest filing, from 1937554.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 873303.0 in Q3 2022 and bottomed at 3841642.0 in Q1 2023.
- Historically, Cash from Operations has averaged 1665052.82 across 5 years, with a median of 1469304.0 in 2024.
- Annual changes were most pronounced in 2022 — Cash from Operations sank 690.29% — and 2024, when it soared 76.65%.
- Creative Medical Technology Holdings' Cash from Operations stood at 3591234.0 in 2022, then surged by 47.23% to 1894983.0 in 2023, then slipped by 2.88% to 1949536.0 in 2024, then rose by 0.61% to 1937554.0 in 2025, then soared by 31.7% to 1323310.0 in 2026.
- Business Quant data shows CELZ's Cash from Operations at 1323310.0 in Q1 2026, 1937554.0 in Q4 2025, and 1168609.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 728.46 Mn |
| 10 | Creative Medical Technology Holdings | 1.85 Mn | 1.85 Mn | - | -1.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.47 Mn |
| Jun 30, 2026 | -1.47 Mn |
| Mar 31, 2026 | -1.32 Mn |
| Mar 31, 2026 | -1.32 Mn |
| Dec 31, 2025 | -1.94 Mn |
| Dec 31, 2025 | -1.94 Mn |
| Sep 30, 2025 | -1.17 Mn |
| Sep 30, 2025 | -1.17 Mn |
| Jun 30, 2025 | -1.16 Mn |
| Jun 30, 2025 | -1.16 Mn |
| Mar 31, 2025 | -1.59 Mn |
| Mar 31, 2025 | -1.59 Mn |
| Dec 31, 2024 | -1.95 Mn |
| Dec 31, 2024 | -1.95 Mn |
| Sep 30, 2024 | -985,588.00 |
| Sep 30, 2024 | -985,588.00 |
| Jun 30, 2024 | -1.47 Mn |
| Jun 30, 2024 | -1.47 Mn |
| Mar 31, 2024 | -896,864.00 |
| Mar 31, 2024 | -896,864.00 |